Peer-reviewed veterinary case report
pANCA antibody linked to treatment response in dogs with diarrhea
By Luckschander, Nicole et al.·Published in Journal of veterinary internal medicine·2006·Department of Clinical Veterinary Medicine·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Perinuclear antineutrophilic cytoplasmic antibody and response to treatment in diarrheic dogs with food responsive disease or inflammatory bowel disease.
- Species:
- dog
Plain-English summary
A group of 65 dogs with diarrhea, some diagnosed with food-responsive disease (FRD) and others with inflammatory bowel disease (IBD), were evaluated to see how a specific antibody (pANCA) related to their treatment outcomes. Dogs with FRD improved significantly after switching to a novel diet, while those with IBD were treated with corticosteroids. Both groups showed a marked decrease in the severity of their symptoms after treatment, with many moving from moderate to severe scores to much milder ones. The study suggests that a positive pANCA test might help identify dogs with FRD, but it didn't correlate with treatment success in either group.
People also search for: dog diarrhea treatment · food-responsive disease in dogs · inflammatory bowel disease in dogs · pANCA test for dogs
Abstract
The goal of this study was to investigate the correlation between perinuclear antineutrophilic cytoplasmic antibody (pANCA) and clinical scores before and after treatment in diarrheic dogs with food-responsive disease (FRD) or inflammatory bowel disease (IBD). pANCA serology was evaluated prospectively by indirect immunofluorescence in 65 dogs with signs of gastrointestinal disease, and if positive, pANCA antibody titers were determined. Thirty-nine dogs with FRD responded to a novel diet, and 26 dogs with IBD were treated with corticosteroids. The severity of clinical signs was scored by means of a canine IBD activity index (CIBDAI). At initial examination, a significantly (P = .002) higher percentage of dogs were pANCA-positive in the FRD group (62%) compared with the IBD group (23%). pANCA titers were significantly higher (P = .003) before treatment in the FRD group (median titer 100) compared with the IBD group (median titer 1). However, there was no difference in pANCA titers between the groups after respective treatments because dogs in the IBD group had a significant increase in pANCA titer after treatment. The CIBDAI score decreased significantly (P < .001) after treatment in both groups (74% moderate to severe in FRD dogs before versus 8% after treatment; 85% moderate to severe in IBD dogs before versus 32% after treatment). There was no correlation between pANCA status in FRD or IBD dogs before treatment and scores for CIBDAI, endoscopy, or histopathology before or after treatment, except for the endoscopic duodenal score in dogs with FRD after treatment (P = .03). A positive pANCA test before therapy may aid in the diagnosis of FRD.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/16594575/